SLINTEC signs agreement with Akbar Pharmaceuticals to engage in medical research

Thursday, 29 September 2016 00:00 -     - {{hitsCtrl.values.hits}}

dft-5-96Akbar Pharmaceuticals Chief Executive Officer Saman Pieris (right) with SLINTEC Chief Executive Officer Harin de Silva Wijeyeratne (Other from left): Ameena Zacky, Dr. Rangika de Silva, Manju Gunawardene, Harin De Silva Wijeyeratne, Saman Pieris, Professor Anil Goonethilake and Maheshika Perera 




Akbar Pharmaceuticals and Sri Lanka Institute of Nanotechnology (SLINTEC) have signed a research agreement to develop a novel medicinal product for Akbar’s Healthcare division. Building on Sri Lankan research, the project aims to develop a product which will aid in patient treatment and wellness. 

SLINTEC is a public-private partnership between the Government of Sri Lanka and major players in the private sector; namely MAS Holdings, Brandix, Dialog, Hayleys, Loadstar and Lankem. SLINTEC is committed to supporting the local industry to improve and develop their products to meet the demands of the local and international markets using nanotechnology and other advanced technology solutions. The project falls under SLINTEC’s Healthcare and Nutraceutical’s platform. 

Akbar Pharmaceuticals is a diverse pharmaceutical company, providing complete pharmaceutical solutions from research and development to distribution. Lina Manufacturing Ltd., which is wholly owned by Akbar Pharmaceuticals was the pioneer in locally manufacturing respiratory-care products, headed by Professor Anil Goonethilake. Akbar’s wide product range includes OTC pharmaceuticals, medical and surgical devices, consumables, nutraceuticals and surgical equipment.